Results 21 to 30 of about 23,901 (228)

Analysis of the subsequent treatment of osteoporosis by transitioning from bisphosphonates to denosumab, using quantitative computed tomography: A prospective cohort study

Bone Reports, 2021
Purpose: Denosumab reduces bone resorption and improves bone mineral density (BMD). Studies have analyzed subsequent treatment transitioning from bisphosphonates to denosumab based on dual-energy X-ray absorptiometry scanning (DXA). Quantitative computed
Koki Tsuchiya, Koji Ishikawa, Yoshifumi Kudo, Soji Tani, Takashi Nagai, Tomoaki Toyone, Katsunori Inagaki   +6 more
doaj   +1 more source

Romosozumab was not effective in preventing multiple spontaneous clinical vertebral fractures after denosumab discontinuation: A case report

Bone Reports, 2020
Discontinuation of denosumab is associated with the increase of bone turnover markers to above-baseline levels (so-called rebound in bone turnover) and rapid bone loss.
Masafumi Kashii, Kosuke Ebina, Kazuma Kitaguchi, Hideki Yoshikawa   +3 more
doaj   +1 more source

Long-term use of denosumab and its association with skeletal-related events and osteonecrosis of the jaw

Scientific Reports, 2023
Denosumab, an inhibitor of receptor activator of nuclear factor kappa-B ligand, reduces skeletal-related events (SREs) and is approved for solid tumors with bone metastases.
Pei-An Fu, Chin-Yao Shen, Shuen‑Ru Yang, Chun-Hui Lee, Hui-Wen Chen, Edward Chia-Cheng Lai, Wei-Pang Chung   +6 more
doaj   +1 more source

A review of denosumab for the treatment of osteoporosis [PDF]

, 2014
Tsuyoshi Miyazaki,1,2 Fumiaki Tokimura,1 Sakae Tanaka3 1Department of Orthopedic Surgery, 2Department of Geriatric Medicine, Tokyo Metropolitan Geriatric Hospital and Institute of Gerontology, Itabashi-ku, Tokyo, Japan; 3Department of Orthopedic Surgery,
Tokimura F, Tanaka S, Sakae Tanaka, Miyazaki T, Tsuyoshi Miyazaki, Fumiaki Tokimura   +5 more
core   +1 more source

Cases

, 2021
A rebound of osteoclast activity during the 2 years after a treatment or prevention of osteoporosis with denosumab (Dmab) leads to an increased risk of vertebral fractures (VFs).
Thierry Buclin, Burckhardt, P., Buclin, T., Mohamed Faouzi, Lamy, O., Faouzi, M., Peter Burckhardt, Olivier Lamy   +7 more
core   +1 more source

Denosumab treatment in patients with different courses of osteoporosis

Остеопороз и остеопатии, 2017
We present three clinical cases of successful osteoporosis treatment with denosumab in patients with different courses of osteoporosis: postmenopausal with bisphosphonates ineffectiveness, osteoporosis of mixed etiology in patient on thyroid stimulating ...
Liudmila Ya. Rozhinskaya, Elizaveta O. Mamedova, Alexander S. Lutsenko, Anastasia A. Malygina, Zhanna E. Belaya   +4 more
doaj   +1 more source

Persistence with Denosumab in Male Osteoporosis Patients: A Real-World, Non-Interventional Multicenter Study [PDF]

Endocrinology and Metabolism, 2023
Background Persistence with denosumab in male patients has not been adequately investigated, although poor denosumab persistence is associated with a significant risk of rebound vertebral fractures.
Chaiho Jeong, Jeongmin Lee, Jinyoung Kim, Jeonghoon Ha, Kwanhoon Jo, Yejee Lim, Mee Kyoung Kim, Hyuk-Sang Kwon, Tae-Seo Sohn, Ki-Ho Song, Moo Il Kang, Ki-Hyun Baek   +11 more
doaj   +1 more source

Clinical utility of denosumab for treatment of bone loss in men and women [PDF]

, 2011
Robert A Adler, Ranjodh S GillEndocrinology and Metabolism, McGuire Veterans Affairs Medical Center, Richmond, VA, USAAbstract: While most older patients with osteoporosis are treated with antiresorptive bisphosphonates such as alendronate, risedronate ...
Adler R, Gill RS, null Gill, Robert Adler   +3 more
core   +1 more source

Elevated Bone Hardness Under Denosumab Treatment, With Persisting Lower Osteocyte Viability During Discontinuation

Frontiers in Endocrinology, 2020
Denosumab is a potent osteoclast inhibitor targeted to prevent osteoporotic bone loss and thereby reduce fractures in the aging population. Recently, an elevated risk of rebound fractures following denosumab discontinuation was identified, unless ...
Katharina Jähn-Rickert, Eva M. Wölfel, Björn Jobke, Christoph Riedel, Maya Hellmich, Mathias Werner, Michelle M. McDonald, Björn Busse   +7 more
doaj   +1 more source

Current indications for denosumab in benign bone tumours

EFORT Open Reviews, 2023
Denosumab is a fully humanised monoclonal antibody to RANK ligand, inhibiting the RANK–RANKL pathway. It promotes the apoptosis of osteoclast-like giant cells, a secondary ossification and connective tissue formation. Given its high efficacy, denosumab
Antal Imre, Sápi Zoltán, Szendrői Miklós   +2 more
doaj   +1 more source